The Pulmonary Fibrosis Foundation (PFF) is welcoming pulmonary fibrosis (PF) patients, caregivers, and lung transplant recipients in the U.S. willing to volunteer as PFF Ambassadors. The PFF Ambassador program is designed to offer hope and inspiration to those affected by PF through public speaking and heightened awareness of this…
Pulmonary Fibrosis Foundation Welcomes ‘Ambassador’ Applicants
Treatment with Ofev (nintedanib) was found to prevent the progression of both cancer and idiopathic pulmonary fibrosis (IPF) in a 75-year-old woman with a history of smoking who was diagnosed with IPF and diffuse squamous cell lung cancer, a recent case study reported. Nevertheless, researchers noted that “scientific data…
How does a person with a chronic, progressive lung disease of unknown origin live their best life? How do they continue to live their best life in a pandemic? In the days immediately following my diagnosis in January 2017, I made a couple key decisions about my relationship with…
Algernon Pharmaceuticals has been notified it will be given a Canadian patent, as requested, covering its investigational oral therapy NP-120 (ifenprodil) for idiopathic pulmonary fibrosis (IPF). Initially developed by Sanofi and approved for the treatment of circulatory disorders in Japan and South Korea, ifenprodil showed anti-scarring and anti-coughing effects…
Supplementary oxygen using a high‐flow nasal cannula boosts exercise endurance more effectively than standard devices in idiopathic pulmonary fibrosis (IPF) patients with suboptimal blood-oxygen levels, a small trial reported. The study, “Impact of high-flow oxygen therapy during exercise in idiopathic pulmonary fibrosis: a pilot crossover clinical trial,” was…
People with rapidly progressing idiopathic pulmonary fibrosis (IPF) have significantly higher levels of circulating cell-free DNA (ccfDNA) than those with slower disease progression and healthy people, a small study shows. In addition, ccfDNA levels, which have been suggested to contribute to IPF, were found to be associated with changes in…
In times of hardship, I’ve found nothing to be more valuable than human connection. After I was diagnosed in 2016 with idiopathic pulmonary fibrosis (IPF), a life-threatening and debilitating lung disease, it felt as though no one could relate. That changed when I started talking with other IPF patients. Sharing…
In commemoration of the International Quality of Life Month happening in January, the Pulmonary Fibrosis Foundation (PFF) is calling attention to the educational resources it offers, which are designed to support and improve the lives of people with pulmonary fibrosis (PF). “This January, start the New Year on…
During an appointment at my clinic shortly after my idiopathic pulmonary fibrosis (IPF) diagnosis a few years ago, I had a conversation with my pulmonologist about clinical trials. That discussion led to my personal commitment to support research as much as possible. The conversation ended with a simple…
The first patient has been enrolled in a pivotal Phase 2b trial investigating the safety and effectiveness of Horizon Therapeutics’ oral medicine candidate HZN-825 in people with idiopathic pulmonary fibrosis (IPF). The trial (NCT05032066) aims to enroll approximately 360 people with IPF, ages 18–80, whose disease symptoms…
